ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "diabetes and rheumatoid arthritis (RA)"

  • Abstract Number: 538 • 2018 ACR/ARHP Annual Meeting

    Type 1 Diabetes in RA: Comparison with Type 2 and Its Association with RA Severity and Treatment

    Sofia Pedro1, Gulsen Ozen2 and Kaleb Michaud1,2, 1FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 2Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: DMARD treatment for Rheumatoid Arthritis (RA) has been shown to improve the glucose control and reduce the incidence of diabetes, usually assumed to be…
  • Abstract Number: 871 • 2017 ACR/ARHP Annual Meeting

    Coronary Microvascular Dysfunction in Rheumatoid Arthritis Compared to Diabetes Mellitus in Patients without Obstructive Coronary Artery Disease

    Katherine P. Liao1, Gabrielle Cremone2, Ethan Lam2, Zhi Yu1, Jon M. Hainer3, Victoria Morgan3, Courtney Bibbo3 and Marcelo Di Carli3, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Nuclear Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Patients with DM have increased coronary microvascular dysfunction (CMD) compared to the general population, leading to higher rates of cardiac death despite normal perfusion…
  • Abstract Number: 2891 • 2017 ACR/ARHP Annual Meeting

    Do Certain Dmards Increase Risk of New-Onset Type 2 Diabetes in RA Patients? a Disease Risk Score Analysis Using Administrative Databases

    E Alemao, Z Guo and L Burns, Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: Data on the association between RA and type 2 diabetes mellitus (T2DM) are inconsistent, suggesting RA treatments such as glucocorticoids (GCs) and hydroxychloroquine could…
  • Abstract Number: 20 • 2016 ACR/ARHP Annual Meeting

    Diabetes and Other Comorbidities in Rheumatoid Arthritis Patients Starting a Biologic DMARD: A Multi-Database Cohort Study

    Seoyoung C. Kim1,2, Yinzhu Jin3, Gregory Brill4, Jennifer Lewey4,5, Nam-Kyong Choi3, Elisabetta Patorno4 and Rishi J. Desai3, 1Rheumatology, Immunology and Allergy and Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, 2Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, 3Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, 4Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, 5Division of Cardiology, Columbia University Medical Center, New York, NY

    Background/Purpose:  Patients with rheumatoid arthritis (RA) are known to have an increased comorbidity burden. Presence of diabetes or other comorbidities such as cardiovascular disease (CVD)…
  • Abstract Number: 990 • 2016 ACR/ARHP Annual Meeting

    Autoimmunity to Multiple Antigens Is Expanded in at-Risk Family Members Beyond the Disease Specific Patterns of the SLE or RA Proband

    Judith A. James1, Krista M. Bean2, Hua Chen2, Kendra A. Young3, Elizabeth A. Bemis4, Jennifer Seifert5, Maria Sargent6, Kevin D. Deane7, Bill Robinson8, David A. Hafler9, Kevin O'Conner10, Jane H. Buckner11, Joel M. Guthridge12, Jill M. Norris13 and V. Michael Holers14, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Epidemiology, University of Colorado Denver, Aurora, CO, 4Epidemiology, Colorado School of Public Health, Aurora, CO, 5University of Colorado, Denver, CO, 6Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 8Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 9Neurology and Immunobiology, Yale School of Medicine, New Haven, CT, 10Yale University, New Haven, CT, 11Benaroya Research Institute at Virginia Mason, Seattle, WA, 12Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 13University of Colorado Denver, Aurora, CO, 14Rheumatology Division, University of Colorado School of Medicine, Aurora, CO

    Background/Purpose:  Certain autoantibodies (aabs) are highly disease specific, can be detected prior to the onset of clinically apparent disease and oftentimes increase in number and…
  • Abstract Number: 2609 • 2015 ACR/ARHP Annual Meeting

    The Measurement of the Skin Autofluorescence As an Indicator of Disease Progression in Rheumatoid Arthritis Patients

    Slawomir Jeka1, Pawel Zuchowski2, Katarzyna Kolossa3, Marta Dura4 and Rafal Wojciechowski5, 1Clinic of Rheumatology and Connective Tissue Diseases, University Hospital Nr 2 Dr. Jan Biziel, 85-168 Bydgoszcz, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland, Bygdoszcz, Poland, 2Independent Section of Scientific Research Coordination and Didactic Activity, University Hospital Nr 2 Dr. Jan Biziel, 85- 168 Bydgoszcz, Poland, Bygdoszcz, Poland, 3Clinic of Rheumatology and Connective Tissue Diseases, University Hospital Nr 2 Dr. Jan Biziel, 85- 168 Bydgoszcz, Poland, Bygdoszcz, Poland, 4Department of Radiology and Medical Imaging, University Hospital Nr 2 Dr. Jan Biziel, 85- 168 Bydgoszcz, Poland, Bygdoszcz, Poland, 5Clinic of Rheumatology and Connective Tissue Diseases, University Hospital Nr 2 Dr. Jan Biziel, 85-168 Bydgoszcz, Poland, Bydgoszcz, Poland

    Background/Purpose:  In course of rheumatoid arthritis (RA) ther is often impaired glucose metabolism, which leads to the development of diabetes mellitus (DM). One of the…
  • Abstract Number: 1040 • 2013 ACR/ARHP Annual Meeting

    Use Of TNF Inhibitors Is Associated With a Reduced Risk Of Diabetes In RA Patients

    Siri Lillegraven1, Jeffrey D. Greenberg2, George W. Reed3, Katherine C. Saunders3, Jeffrey R. Curtis4, Leslie R. Harrold5, Marc C. Hochberg6, Dimitrios A. Pappas7, Joel M. Kremer8 and Daniel H. Solomon9, 1Diakonhjemmet Hospital, Oslo, Norway, 2NYU Hospital for Joint Diseases, New York, NY, 3Corrona, LLC., Southborough, MA, 4Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5University of Massachusetts Medical School, Worcester, MA, 6Medicine, University of Maryland School of Medicine, Baltimore, MD, 7Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, 8Center for Rheumatology, Albany Medical College, Albany, NY, 9Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA

    Background/Purpose: Inflammation may contribute to diabetes risk, and some studies indicate that certain DMARDs might be associated with a reduced risk of diabetes. Most studies…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.